Tifcemalimab 是一种人源化抗BTLA(B和T淋巴细胞衰减因子) 单克隆抗体。Tifcemalimab 通过与 BTLA 结合，阻断 HVEM-BTLA 的相互作用，从而阻断 BTLA 介导的抑制信号通路。Tifcemalimab 可用于癌症的研究。
| 生物活性 | Tifcemalimab (JS004) is a humanized anti-BTLA(B and T lymphocyte attenuation factor)monoclonal antibody. Tifcemalimab blocks the interaction of HVEM-BTLA by binding toBTLA, and thus blocks the inhibitory signaling pathway mediated byBTLA. Tifcemalimab can be used in research ofcancer[1]. |
| IC50& Target | |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
m.cnreagent.com